Wire · opportunities
Merck axes $2.7B BTK inhibitor program after seeing phase 3 data
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
Merck has discontinued its $2.7 billion BTK inhibitor nemtabrutinib program after phase 3 trial data indicated the treatment's risks may outweigh benefits for chronic lymphocytic leukemia and small lymphocytic lymphoma patients.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech oncology project just lost a major competitor in BTK inhibitors. If you develop alternative blood cancer treatments, this opens a window to capture orphaned patients and partners left by Merck's exit.
◆ Coverage
1 source · 18 Nov 2026
◆ Related on Wire
◆ Topics
Biotechclinical-trial-failureoncologyBTK-inhibitorMerckdrug-development